| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3402816 | Enfermedades Infecciosas y Microbiología Clínica | 2008 | 9 Pages |
Abstract
In the last few years, new antifungal agents have been introduced with the aim of improving the prognosis of some clinical presentations of this disease. The echinocandins and second-generation triazoles show greater antifungal activity than fluconazole. Moreover, clinical trials of candidiasis in different localizations have shown that these drugs have excellent efficacy and safety profiles. The potential for drug interactions with some of these antifungal agents is considerable. The contribution of the new antifungal drugs in the treatment of candidiasis should be defined in the near future.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
Javier Pemán, Benito Almirante,